Our approach combining causal methodologies with single-cell transcriptomic data not only advances our understanding of the protective roles of CD4+ T cells in CRC risk, but also highlights potential therapeutic targets for CRC prevention. This evidence concerns the gene CD4 and colorectal carcinoma.